Last checked at 13 Dec 2019 12:12
ImmuPharma To List On Life Sciences Heavy Brussels Index
ImmuPharma To List On Life Sciences Heavy Brussels Index
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Immupharma Share News (IMM)
IMM Share
Price
IMM Share
News
IMM Share
Chat
IMM Share
Trades1
IMM
Live RNS
IMM Share
Charts
IMM Level 2
Console
IMM Live
Share Price
IMM Broker
Ratings
IMM Directors
Deals
IMM Financial
Diary
IMM
Fundamentals
IMM Short
Positions
IMM
Media
Immupharma Information
Share Price Information for Immupharma (IMM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.14
Bid:
2.10
Ask:
2.19
Change:
0.00 (0.00%)
Spread:
0.09 (4.286%)
Open:
2.14
High:
0.00
Low:
0.00
Prev. Close:
2.14
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.11 Dec 2019 14:54
ImmuPharma says not looking to raise funds
(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.
Read more11 Dec 2019 14:03
ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise
ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise
Read more28 Nov 2019 16:26
ImmuPharma shares soar as it teams up with Avion on Lupuzor
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.
Read more28 Nov 2019 12:02
Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion
Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion
Read more28 Nov 2019 07:28
ImmuPharma licenses lupus drug Lupuzor to Avion in the United States
LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....
Read more30 Sep 2019 10:40
ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval
ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval
Read more28 Jun 2019 12:01
Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor
(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug
Read more28 Jun 2019 10:27
ImmuPharma pleased with Lupuzor open-label study results
(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.
Read more26 Jun 2019 11:15
Immupharma raises ?2.66m from subscription agreement with institutional investor
(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.
Read more26 Jun 2019 10:14
Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead
(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development
Read more24 May 2019 11:47
Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline
LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a
Read more7 May 2019 11:06
ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)
LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a
Read more1 Apr 2019 14:07
ImmuPharma Loses Exclusivity Period For Talks With Incanthera
LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a
Read more14 Mar 2019 11:04
ImmuPharma struggles to convince investors in latest update
(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.
Read more